Joel Isaacson & Co. LLC Has $10.36 Million Position in Johnson & Johnson (NYSE:JNJ)

Joel Isaacson & Co. LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 71,606 shares of the company’s stock after acquiring an additional 431 shares during the period. Joel Isaacson & Co. LLC’s holdings in Johnson & Johnson were worth $10,356,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. AMF Tjanstepension AB raised its holdings in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after purchasing an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC bought a new position in Johnson & Johnson during the third quarter valued at about $209,000. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson in the third quarter worth about $213,000. Rise Advisors LLC boosted its stake in shares of Johnson & Johnson by 3.2% during the 3rd quarter. Rise Advisors LLC now owns 3,134 shares of the company’s stock worth $508,000 after acquiring an additional 96 shares in the last quarter. Finally, Willis Investment Counsel raised its stake in shares of Johnson & Johnson by 0.3% in the 3rd quarter. Willis Investment Counsel now owns 308,892 shares of the company’s stock valued at $50,059,000 after acquiring an additional 863 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent analyst reports. Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $154.22 on Tuesday. The firm has a market capitalization of $371.31 billion, a PE ratio of 23.19, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The firm has a 50-day moving average price of $147.42 and a 200 day moving average price of $156.08.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the company earned $2.29 EPS. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.22%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.